On 8 January 2025, Galapagos NV announced that it intends to spin-off approximately €2.45 billion in cash into a new SpinCo, which will focus on building a pipeline of innovative medicines through transformational transactions. Following the separation, Galapagos expects to have about €500 million in cash and will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.
Eubelius assists Gilead Sciences, Inc. in the proposed separation of Galapagos into two listed entities and in entering into certain material agreements.
The Eubelius team is being led by Joris De Wolf (Corporate and M&A), and further consists of Wouter Claes (Tax), Thomas Donnez (Banking and finance), Sylvain Guéret (Banking and finance) and Thijs Keuleers (Corporate and M&A).
For more information, see Galapagos’ press release.
